After a decades-long wait, the FDA is on the brink of approving a landmark rare disease treatment — the first to rely on a Nobel prize-winning technique known as RNA interference, or RNAi.

The widely anticipated approval will be a watershed moment not only for its manufacturer, Alnylam, but for the broader field of research into RNAi, which lets scientists mute genes that aren’t functioning properly. The FDA must announce its decision by Friday to meet a regulatory deadline.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Gee everyone will want this. The current corruption at our regulatory agencies, along with profit incentives related to “Rare Diseases” makes it the perfect time to market this product. Most of the research is Proprietary (secret) anyway. We won’t know of adverse events until long after this stuff has reached market saturation. After all those clever industry insiders believe that Healthcare is a choice, anyone desperate enough to choose to try this will only have themselves to blame.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy